



Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park
Sanderson Road
Uxbridge
Middlesex UB8 1DH
England

Registered in Cardiff - UK N° GE87

Dr. Eric Abadie
European Medicines Agency
7, Westferry Circus
London E14 4KB
United Kingdom

18 March 2009

Dear Dr. Abadie,

Subject: Withdrawal of IXEMPRA, (ixabepilone) EMEA/H/C/000930

I would like to inform you that, at this point of time, Bristol-Myers Squibb Pharma EEIG has taken the decision to withdraw the application for the Marketing Authorisation of IXEMPRA (ixabepilone), 2mg/ml, powder and solvent for concentrate for solution for infusion.

The withdrawal is based on the following reasons:

- The CHMP considers that the new elements provided in the re-examination procedure did not allow the committee to change their view on the benefit risk balance of ixabepilone in combination with capecitabine in the treatment of patients with metastatic breast cancer failing prior taxanes and anthracyclines.

Patients who are currently receiving ixabepilone under the compassionate use program will continue to receive the product. Bristol-Myers Squibb remains committed to study ixabepilone in breast cancer and in other tumour types.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,